Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study

Laura J. Rasmussen-Torvik*, Berta Almoguera, Kimberly F. Doheny, Robert R. Freimuth, Adam S. Gordon, Hakon Hakonarson, Jared B. Hawkins, Ammar Husami, Lynn C. Ivacic, Iftikhar J. Kullo, Michael D. Linderman, Teri A. Manolio, Aniwaa Owusu Obeng, Renata Pellegrino, Cynthia A. Prows, Marylyn D. Ritchie, Maureen E. Smith, Sarah C. Stallings, Wendy A. Wolf, Kejian ZhangStuart A. Scott

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

There has been extensive debate about both the necessity of orthogonal confirmation of next-generation sequencing (NGS) results in Clinical Laboratory Improvement Amendments–approved laboratories and return of research NGS results to participants enrolled in research studies. In eMERGE-PGx, subjects underwent research NGS using PGRNseq and orthogonal targeted genotyping in clinical laboratories, which prompted a comparison of genotyping results between platforms. Concordance (percentage agreement) was reported for 4077 samples tested across nine combinations of research and clinical laboratories. Retesting was possible on a subset of 1792 samples, and local laboratory directors determined sources of genotype discrepancy. Research NGS and orthogonal clinical genotyping had an overall per sample concordance rate of 0.972 and per variant concordance rate of 0.997. Genotype discrepancies attributed to research NGS were because of sample switching (preanalytical errors), whereas the majority of genotype discrepancies (92.3%) attributed to clinical genotyping were because of allele dropout as a result of rare variants interfering with primer hybridization (analytical errors). These results highlight the analytical quality of clinically significant pharmacogenetic variants derived from NGS and reveal important areas for research and clinical laboratories to address with quality management programs.

Original languageEnglish (US)
Pages (from-to)561-566
Number of pages6
JournalJournal of Molecular Diagnostics
Volume19
Issue number4
DOIs
StatePublished - Jul 2017

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study'. Together they form a unique fingerprint.

  • Cite this

    Rasmussen-Torvik, L. J., Almoguera, B., Doheny, K. F., Freimuth, R. R., Gordon, A. S., Hakonarson, H., Hawkins, J. B., Husami, A., Ivacic, L. C., Kullo, I. J., Linderman, M. D., Manolio, T. A., Obeng, A. O., Pellegrino, R., Prows, C. A., Ritchie, M. D., Smith, M. E., Stallings, S. C., Wolf, W. A., ... Scott, S. A. (2017). Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study. Journal of Molecular Diagnostics, 19(4), 561-566. https://doi.org/10.1016/j.jmoldx.2017.04.002